Roquefort Therapeutics to acquire cancer drug licence in £32m RTO deal and raise £8.5m

Roquefort Therapeutics, currently valued at under £1.5m, is acquiring an exclusive worldwide licence to AO-252 — an oral TACC3-targeting cancer drug — for £31.875m satisfied via new shares and is concurrently raising £8.5m via a placing at 10p per share to fund development through 2026–27. The phase I asset, which can cross the blood-brain barrier and has shown up to 29% tumour reductions at low doses, is already in US trials and the company targets material data readouts by Q4 to support commercial and partnership discussions; the transaction includes a board overhaul, management investment, an AIM admission and a name change to Coiled Therapeutics. The enlarged group will also assess Roquefort’s STAT‑6 programme, creating a two-asset pipeline, while citing a recent $3.05bn industry precedent to highlight potential commercial value in the prostate/oncology space.

Analysis

Market structure: The deal turns micro‑cap ROQ (to be COIL) into a clinical‑stage oncology play focused on AO‑252 (TACC3 inhibitor) with BBB penetration — a differentiated asset versus many oral kinase programs and potentially attractive to Big Pharma buyers (JNJ precedent $3.05bn). Immediate winners: new management/Coiled Therapeutics founders (insider equity + board control), short‑term investors in the 10p placing; losers: legacy Main Market investors who face dilution and loss of access when the listing moves to AIM, and any small‑cap peers competing for attention/capital.

Risk assessment: Tail risks are high — phase I/II readouts could show no durable responses or safety issues (DMC stop), IP disputes with A2A/Coiled, or failure to secure partners leading to >50% dilution or insolvency. Timeframe bifurcation: expect acute volatility on reorg/placing and AIM admission (days–weeks), primary catalyst windows through Q4 2026 (data readouts) and partnership discussions in 2027; longer term (2–4 years) outcomes hinge on Phase II success/commercial deals. Hidden dependencies include enrollment pace in US trial, proprietary biomarkers for TACC3, and the economics of the share‑paid licence that may trigger earn‑outs or milestone dilution.

Trade implications: For knowledgeable allocators, this is an event‑driven, high‑binary trade: the $8.5m cash runway covers ops into 2027 but not late‑stage development — positive Q4 data could revalue shares by multiples and attract M&A, negative data can wipe out equity. Direct actionable structures: (a) participate in placing (if access) to secure 10p shares and avoid market premia on listing; (b) size exposure small (1–2% NAV) with strict 50% stop and 12‑18 month horizon tied to Q4 2026 readouts; (c) hedge idiosyncratic downside with 6–12 month put exposure on XBI/IBB sized 25–50% of the long notional.

Contrarian angles: Consensus may underweight the strategic value of BBB penetration for brain mets (can justify acquisition premiums >5x typical Phase I comparables) but may also overrate the JNJ precedent — most Big Pharma buys target clear signal of efficacy and biomarker. Historical parallels (microcap RTOs that failed pre‑proof‑of‑concept) warn that relisting on AIM reduces institutional bid interest and increases volatility; unintended consequences include insider concentration risk from founders investing only £500k each versus the £31.9m licence consideration paid in equity.

Key Decisions for Investors

• If you can access the placing, consider subscribing up to a 1% portfolio allocation at 10p to obtain a pro rata position ahead of AIM admission — pricing avoids aftermarket premium but cap size because of binary risk; hold 12–18 months to Q4 2026 data.
• Establish a tactical long position in ROQ/COIL sized 1–2% NAV post‑placing (or buy market shares after AIM admission) with a 50% stop‑loss and target discretionary take‑profits at 200% and 400% if Phase I signals broaden to ORR >20% in expansion cohorts.
• Hedge downside by buying 6–12 month puts on XBI (or IBB) sized to 25–50% of the ROQ/COIL long notional (e.g., buy 30% OTM puts) to protect against sector‑wide derisking or negative trial contagion.
• If a pharma partnership or acquisition indication is announced pre‑Q4 2026, reduce exposure to 50% of initial size and lock gains; conversely, if enrollment or safety flags arise within 60 days, exit entirely to preserve capital.